氯贝丁酯

C₁₂H₁₅ClO₃

242.70

1913459

211-277-4

MFCD00000615

24278085

NA.77

Clofibrate has been used:

• as a quinolinate phosphoribosyltransferase (QPRT) agonist to study its effects on hepatitis C virus (HCV) infection
• as peroxisome proliferated activated receptor (PPAR) agonist to study its effects on autophagy in rat liver cells
• as a hepatotoxicant to study its effects on gene expression in primary rat hepatocytes

Clofibrate is a peroxisome proliferated activated receptor α (PPARα) agonist. It is a fibric acid derivative and has a therapeutic effect on hypertriglyceridemia and hyperlipoproteinemia type III. Clofibrate participates in lowering the very-low-density lipoprotein (VLDL) and cholesterol levels in hyperlipoproteinemia type III patients. It facilitates the decrease of total serum bilirubin concentration in Gilbert′s syndrome.

This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Wyeth. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

liquid

200

clear colorless

1.14 g/mL at 25 ℃ (lit.)

Wyeth

2-8℃

CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1

1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3

KNHUKKLJHYUCFP-UHFFFAOYSA-N

human ... PPARA(5465)
mouse ... Ppara(19013)

250 mg in glass bottle
1, 5, 10 g in glass bottle
Bottomless glass bottle. Contents are inside inserted fused cone.

GHS05,GHS07

Danger

H302 - H315 - H318 - H335

P261 - P264 - P280 - P301 + P312 - P302 + P352 - P305 + P351 + P338

Acute Tox. 4 Oral - Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3

Respiratory system

10 - Combustible liquids

WGK 3

235.4 °F - closed cup

113 ℃ - closed cup

Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter